February 27, 2023 – Therapy with DNA repair inhibitors in early phase clinical trials

In conclusion, 111In-girentuximab SPECT is usually a feasible FU imaging modality after ccRCC cryoablation and may aid in the early detection of residual or recurrent ccRCC

February 27, 2023 climat2050

In conclusion, 111In-girentuximab SPECT is usually a feasible FU imaging modality after ccRCC cryoablation and may aid in the early detection of residual or recurrent

Day: February 27, 2023

﻿In conclusion, 111In-girentuximab SPECT is usually a feasible FU imaging modality after ccRCC cryoablation and may aid in the early detection of residual or recurrent ccRCC

In conclusion, 111In-girentuximab SPECT is usually a feasible FU imaging modality after ccRCC cryoablation and may aid in the early detection of residual or recurrent ccRCC